Enact Holdings Inc

NASDAQ: ACT
$29.95
+$0.01 (+0.0%)
Closing price April 26, 2024
Enact Holdings, Inc. operates as a private mortgage insurance company in the United States. The company engages in writing and assuming residential mortgage guaranty insurance. It also offers private mortgage insurance products primarily insuring prime-based, individually underwritten residential mortgage loans; and contract underwriting services for mortgage lenders. It primarily serves residential mortgage loan originators. The company was formerly known as Genworth Mortgage Holdings, Inc. and changed its name to Enact Holdings, Inc. in May 2021. Enact Holdings, Inc. was founded in 1981 and is headquartered in Raleigh, North Carolina. Enact Holdings, Inc. operates as a subsidiary of Genworth Holdings Inc.

US-Focused Cannabis ETF Debuts
A new ETF that includes only U.S. firms operating in the legal cannabis market made its first appearance on Wednesday.
Paul Ausick
Published:
Last Updated:

Is This a Buying Opportunity for Cannabis ETFs Going Into 2020?
Many investors are focused on getting the jump on the cannabis industry, but they aren’t alone. With this increased speculation, there is added risk that has to be considered.
Chris Lange
Published:
Last Updated:

5 ETFs Targeting Sinners
The ETF universe includes a variety of funds that allow investors to share in the spoils of legal gambling, smoking (tobacco and marijuana), and beer and spirits consumption. Investing in sin can pay...
Paul Ausick
Published:

Wall Street Has a New Strategy for Legal Marijuana - Whenever That Happens
With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged. Investors can use a number of ETFs to invest in the future of cannabis.
Chris Lange
Published:

What a Combined Allergan and Pfizer Might Actually Look Like
Allergan has issued a press release that confirms some of the rumors floating in the market that it has been approached by Pfizer.
Jon C. Ogg
Published:

Large Companies With Fastest Revenue and Earnings Growth in 2015
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
Chris Lange
Published:

American Airlines Replaces Allergan in S&P 500
American Airlines will be the newest addition to the S&P 500, taking the place of Allergan.
Chris Lange
Published:

6 Stocks Will See Massive Buying and Selling on S&P Quarterly Rebalance
All indexes rebalance on a quarterly basis. 24/7 Wall St. screened a recent Jefferies report for the stocks that will see the most trading on Friday's rebalance.
Lee Jackson
Published:

As Valeant Ups Salix Buyout, Will Endo Come Back?
Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based on a new price for Salix shares.
Chris Lange
Published:

UBS Makes Big Changes to Equity Focus List For March
A new report from UBS shows some serious changes made to the firm's Equity Focus list for March.
Lee Jackson
Published:

Is the Actavis $21 Billion Bond Sale Just the First?
Actavis launched second-largest ever bond sale Monday to raise $21 billion to pay for its acquisition of Allergan.
Paul Ausick
Published:
Last Updated:

UBS Quality Growth at a Reasonable Price Stocks Beating the S&P 500
The UBS CIO Wealth Management team makes a good case that investors should consider the stocks in the firm's Quality Growth at a Reasonable Price (Q-GARP) portfolio.
Lee Jackson
Published:

Merrill Lynch's Top Health Care Stock Picks for 2015
24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.
Chris Lange
Published:
Last Updated:

9 Big Stocks That Doubled in 2014
Here is a look at the top performers for 2014, nine stocks that have doubled and have a current market cap of at least $5 billion.
Paul Ausick
Published:
Last Updated:

What a Generic Celebrex Means for Pfizer and for Actavis
While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in America.
Jon C. Ogg
Published: